Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines

Advances in Experimental Medicine and Biology

Volumn 491, Issue , 2001, Pages 369-402

  Hakomori, S I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PEPTIDE LIBRARY; SIALIC ACID; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CONFERENCE PAPER; GLYCOSYLATION; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

THAIS;

EID: 0034963231     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1267-7_24     Document Type: Conference Paper

References (193)

1. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism
2. Database of p53 gene somatic mutations in human tumors and cell lines
3. New tumor suppressor may rival p53
4. p53: Puzzle and paradigm
5. p53, the cellular gatekeeper for growth and division
6. Landscaping the cancer terrain
7. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
8. Expression of Ley and extended Ley blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues
9. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer
10. Carbohydrate signals in metastasis and prognosis of human carcinomas
11. Polysaccharides and a glycidamin in gastric cancer tissue
12. Molisch-positive mucopolysaccharides of gastric cancers as compared with the corresponding components of gastric mucosae. First report: Fractionation procedure of gastric cancer and gastric mucosa
13. A, B, and O substances in gastrointestinal carcinoma
14. Loss of isoantigens A, B, and H in carcinoma of the lung
15. Isoantigens A, B, and H in benign and malignant lesions of the cervix
16. Loss of epithelial blood group antigens A and B in oral premalignant lesions
17. Blood group ABH-related antigens in normal and malignant bladder urothelium: Possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas
18. Tissue antigens A, B and H in health and disease
19. Expression of blood-group antigen A: A favorable prognostic factor in non-small-cell lung cancer
20. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas
21. Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: Approach with A and B gene transfection
22. Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy
23. Deletion of A-antigen in human cancer cell lines is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter
24. β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia
25. Oncodevelopmental expression of -GlcNAcβ1-6Manα1-6Manβ1-6 branching of Asn-linked oligosaccharides in human breast carcinomas
26. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides
27. Remodeling of cell surface glycoproteins by N-acetylglucosaminyltransferase III gene transfection: Modulation of metastatic potentials and down regulation of hepatitis B virus replications
28. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection
29. Characterization of structural determinants required for the high-affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins
30. Prognostic value of β1,6-branched oligosaccharides in human colorectal carcinoma
31. Galactosylgloboside expression in seminoma: Inverse correlation with metastatic potential
32. Elevation of an α(1,3)fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT-29
33. Ley antigen expression is correlated with apoptosis (programmed cell death)
34. Ein vermehrungsfähiges agens als veränderer des isoagglutinatorischen verhaltens der roten blutkörperchen, eine bisher unbekannte quelle der fehlbestimmungen
35. Untersuchungen über das von O. Thomsen beschriebene vermehrungsfähige agens als veränderer des isoagglutinatorischen verhaltens der roten blutkörperchen
36. Anemie hemolytique acquise avec polyagglutinabilite des hematies par un nouveau factor present dans le serum humain normal (anti-Tn)
37. Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (anti-Tn)
38. Cryptic A-like receptor sites in human erythrocyte glycoproteins: Proposed nature of Tn-antigen
39. Structural studies on human erythrocyte glycoproteins: Alkali-labile oligosaccharides
40. Interaction of blood-group MN-like cancer antigen and human cytotoxin
41. Human blood-group MN and precursor specificities: Structural and biological aspects
42. T and Tn, general carcinoma autoantigens
43. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: Its identification as Tn antigen
44. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen
45. Elucidation of an essential structure recognized by an anti-GalNAcα-Ser(Thr) monoclonal antibody (MLS 128)
46. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour
47. Prediction of lymph node involvement in breast cancer
48. Helix pomatia in breast cancer
49. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells
50. Expression of sialyl-Tn, Tn and T antigens in primary liver cancer
51. A monoclonal antibody (B72.3) defines patterns ora novel tumor-associated antigen in human mammary carcinoma cell populations
52. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3
53. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked associated O-linked sialosyl-2→6 α-N-acetylgalactosaminyl (sialosyl-Tn) epitope
54. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAcα2→6GalNAc, in mucin-type glycoproteins
55. Purification and characterization of bovine and ovine submaxillary mucins
56. Different modes of sialyl-Tn expression during malignant transformation of human colonic carcinoma
57. Tumor-associated sialylated antigens are constitutively expressed in normal human colonic mucosa
58. Sialosyl-Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients
59. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer
60. Immunohistochemical study of Tn, sialosyl-Tn and T antigens in human meningiomas
61. Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer
62. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: Relation to dysplasia and DNA aneuploidy
63. Differences in sialyl-Tn antigen expression between keratoacanthomas and cutaneous squamous cell carcinomas
64. Serological studies on CEA, CA 19-9, STn, and SLX in colorectal cancer
65. Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis
66. Cloning and expression of a human gene encoding an N-acetylgalactosamine-α2,6-sialyltransferase (ST6GalNAc I): A candidate for synthesis of cancer-associated sialyl-Tn antigens
67. Immunochemical studies on blood groups: XXXIV. Structures of some oligosaccharides produced by alkaline degradation of blood group A, B, and H substances
68. The monoclonal antibody directed to difucosylated type 2 chain (Fucα2→2Galβ1→4[Fucα1→3]G1cNAc; Y determinant)
69. A monoclonal antibody against human colonic adenoma recognizes difucosylated type 2 blood group chains
70. Mouse monoclonal antibody F-3 recognizes the difucosyl type 2 blood group structure
71. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas
72. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on Ley antigen-expressing human cancer cells
73. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: Influence of affinity, size, and stability
74. Novel fucolipids of human adenocarcinoma: Monoclonal antibody specific for trifucosyl Ley (III3FucV3FucVI2FucnLc6), and a possible three-dimensional epitope structure
75. Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen
76. A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis
77. Correlation of expression of H/Ley/Leb antigens with survival in patients with carcinoma of the lung
78. The lectins: Carbohydrate-binding proteins of plants and animals
79. The binding site for fucose-binding proteins of Lotus tetragonolobus is a prognostic marker for transitional cell carcinoma of the human urinary bladder
80. Fucose and sialic acid in glycoproteins of the mucus of the digestive tract
81. Specific antigen in serum of patients with colon carcinoma
82. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II
83. Biosynthesis of the cancer-associated sialyl-Lea antigen
84. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as mucin
85. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer
86. Novel fucolipids accumulating in human cancer: III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6)
87. Characterization of sialosylated Lewisx as a new tumor-associated antigen
88. Glycolipid antigens of human polymorphonuclear neutrophils and the inducible HL-60 myeloid leukemia line
89. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study
90. Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma
91. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA
92. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex
93. Possible new directions in cancer therapy based on aberrant expression of glycosphingolipids: Anti-adhesion and ortho-signaling therapy
94. A carbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1
95. Adhesion of human cancer ceils to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A
96. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium
97. Novel endothelial cell activation factor(s) released from activated platelets which induce E-selectin expression and tumor cell adhesion to endothelial cells: A preliminary note
98. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells
99. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x
100. Selectin ligands
101. Selectin-carbohydrate interactions and the initiation of the inflammatory response
102. Monosialogangliosides of human myelogenous leukemia HL60 cells and normal human leukocytes. 1. Separation of E-selectin binding from nonbinding gangliosides, and absence of sialosyl-Lex having tetraosyl to octaosyl core
103. Monosialogangliosides of human myelogenous leukemia HL60 cells and normal human leukocytes. 2. Characterization of E-selectin binding fractions, and structural requirements for physiological binding to E-selectin
104. Sialosyl-fucosyl poly-LacNAc without the sialosyl-Lex epitope as the physiological myeloid cell ligand in E-selectin-dependent adhesion: Studies under static and dynamic flow conditions
105. The α1→3 fucosylation at the penultimate GlcNAc catalyzed by fucosyltransferase VII is blocked by internally fucosylated residue in sialosyl long-chain poly-LacNAc: Enzymatic basis for expression of physiological E-selectin epitope
106. Expression cloning of a functional glycoprotein ligand for P-selectin
107. P-selectin-dependent adhesion of human cancer cells: Requirement for co-expression of a "PSGL-1-like" core protein and the glycosylation process for sialosyl-Lex or sialosyl-Lea
108. A novel tumor-associated, developmentally regulated glycolipid antigen defined by monoclonal antibody ACFH-18
109. Erythroglycan, a high molecular weight glycopeptide with the repeating structure [galactosyl-(1→4)-2-deoxy-2-acetamido-glucosyl(1→3)] comprising more than one-third of the protein-bound carbohydrate of human erythrocyte stroma
110. Novel tri- and tetrasialylpoly-N-acetyllactosaminyl gangliosides of human placenta: Structure determination of pentadeca- and eicosaglycosylceramides by methylation analysis, fast atom bombardment mass spectrometry, and 1H-NMR spectroscopy
111. A series of disialogangliosides with binary 2-3 sialosyllactosamine structure, defined by monoclonal antibody NUH2, are oncodevelopmentally regulated antigens
112. Lea-active heptaglycosylceramide, a hybrid of type 1 and type 2 chain, and the pattern of glycolipids with Lea, Leb, X (Lex) and Y (Ley) determinants in human blood cell membranes (ghosts): Evidence that type 2 chain can elongate repetitively but type 1 chain cannot
113. A carbohydrate epitope associated with human squamous lung cancer
114. Human tumor-associated Lea-Lex hybrid carbohydrate antigen IV3(Galβ1→3[Fucα1→4]GlcNAc)III3FucnLc4 defined by monoclonal antibody 43-9F: Enzymatic synthesis, structural characterization, and comparative reactivity with various antibodies
115. Carbohydrate antigen defined by a monoclonal antibody raised against a gastric cancer xenograft
116. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Lea (Lea/Lea) epitope
117. Extended type 1 chain glycosphingolipids: Dimeric Lea (III4V4Fuc2Lc6) as human tumor-associated antigen
118. Extended type-1 chain glycosphingolipid antigens: Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)
119. Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Leb/Lea glycosphingolipid, a novel extended type 1 chain antigen
120. Isolation and characterization of gangliosides with a new sialosyl linkage and core structure: Gangliosides of human erythrocyte membranes II
121. A monoclonal antibody directed to N-acetylneuraminosyl α2→6galactosyl residue in gangliosides and glycoproteins
122. New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3
123. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast
124. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland
125. Prognostic significance of the CaMBr1 antigen on breast carcinoma: Relevance of the type of recognised glycoconjugate
126. Immunohistochemical reactivity of a monoclonal antibody prepared against human breast carcinoma
127. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
128. Common tetrasaccharide epitope NeuAcα2→3Galβ1→3(NeuAcα2→6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities
129. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential
130. Expression of globo-series gangliosides in human renal cell carcinoma
131. Fucosyl GM1 - A ganglioside associated with small cell lung carcinomas
132. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1
133. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) in serum
134. Lipid composition of human malignant melanoma tumors at various levels of malignant growth
135. A cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas
136. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2
137. GD3, a prominent ganglioside of human melanoma: Detection and characterization by mouse monoclonal antibody
138. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma
139. Human antibody to OFA-1, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human β-lymphoid cell lines
140. Ganglioside GM2 as a human tumor antigen (OFA-I-1)
141. Identification of human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2
142. Human melanoma antigen AH is an autoantigen ganglioside related to GD2
143. Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma
144. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen
145. Ganglioside expression in melanomas from Japanese individuals: Unusual pattern in two patients with metastatic lesions of acral lentiginous melanomas
146. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
147. Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metastatic melanoma
148. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases
149. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: Selection of low antigenic variants in vivo
150. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen
151. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
152. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines
153. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale
154. Production of monoclonal antibodies specific for distinct portions of the glycolipid asialo GM2 (gangliotriosylceramide)
155. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients
156. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine
157. GD3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines
158. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients
159. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2
160. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
161. ABH and related histo-blood group antigens: Immunochemical differences in carrier isotypes and their distribution
162. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
163. Synthetic vaccines: Synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins
164. Synthetic carbohydrate vaccines: Synthesis and immunogenicity of Tn antigen conjugates
165. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy
166. Induction of Tn (α-N-acetylgalactosamine-O-serine/threonine) antigen-mediated cellular immune response for active immunotherapy in mice
167. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
168. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
169. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: Synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm
170. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant
171. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies
172. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen
173. Searching for peptide ligands with an epitope library
174. Random peptide libraries: A source of specific protein binding molecules
175. Peptides on phage: A vast library of peptides for identifying ligands
176. A family of concanavalin A-binding peptides from a hexapeptide epitope library
177. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics
178. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen
179. A Lewisy epitope mimicking peptide induces anti-Lewisy immune responses in rabbits and mice
180. Preparation of peptides which mimic glycosphingolipids by using phage peptide library and their modulation on β-galactosidase activity
181. GD1α-replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis
182. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses
183. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines
184. Ganglioside GD1α functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue
185. Cell adhesion, spreading, and motility of GM3-expressing cells based on glycolipid-glycolipid interaction
186. Cell adhesion in a dynamic flow system as compared to static system: Glycosphingolipid-glycosphingolipid interaction in the dynamic system predominates over lectin- or integrin-based mechanisms in adhesion of B16 melanoma cells to non-activated endothelial cells
187. Inhibition of B16 melanoma metastasis by administration of GM3- or Gg3-liposomes: Blocking adhesion of melanoma cells to endothelial cells (anti-adhesion therapy) via inhibition of GM3-Gg3Cer or GM3-LacCer interaction
188. Role of gangliosides in tumor progression
189. CD44 in colon cancer
190. A close association of GM3 with c-Src and Rho in GM3-enriched microdomains at the B16 melanoma cell surface membrane: A preliminary note
191. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells
192. Cell recognition and subsequent signal transduction through glycosphingolipid-glycosphingolipid interaction
193. Globoside-dependent adhesion of human embryonal carcinoma cells, based on carbohydrate-carbohydrate interaction, initiates signal transduction and induces enhanced activity of transcription factors AP1 and CREB